Published in Vaccine on November 25, 2004
Recombinant nipah virus vaccines protect pigs against challenge. J Virol (2006) 1.25
How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol (2010) 1.23
Role of CCL5 (RANTES) in viral lung disease. J Virol (2006) 1.21
Respiratory viruses and eosinophils: exploring the connections. Antiviral Res (2009) 1.06
Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice. Vaccine (2006) 1.06
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses (2014) 1.04
The evolution of poxvirus vaccines. Viruses (2015) 1.02
A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One (2009) 0.95
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease. Clin Vaccine Immunol (2015) 0.92
Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic. J Gen Virol (2008) 0.85
The development of an AIDS mucosal vaccine. Viruses (2010) 0.79
A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus. Arch Virol (2013) 0.78
Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells. PLoS One (2015) 0.75
Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design. Int J Mol Sci (2017) 0.75
A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol (2005) 7.94
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Bronchiolitis. Lancet (2006) 3.16
Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med (2004) 2.54
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14
Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med (2009) 2.10
Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med (2002) 2.03
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A (2002) 1.85
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med (2006) 1.82
Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol (2008) 1.76
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67
IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med (2014) 1.67
Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. Am J Respir Crit Care Med (2015) 1.65
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol (2004) 1.58
CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol (2010) 1.51
Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol (2007) 1.50
Open source clinical science for emerging infections. Lancet Infect Dis (2014) 1.47
Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.40
Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax (2012) 1.40
The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol (2008) 1.35
Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine (2003) 1.34
Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol (2013) 1.34
Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol (2006) 1.33
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology (2007) 1.32
Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol (2007) 1.30
Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol (2008) 1.26
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res (2004) 1.26
Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol (2005) 1.24
Role of CCL5 (RANTES) in viral lung disease. J Virol (2006) 1.21
Construction and isolation of recombinant MVA. Methods Mol Biol (2004) 1.19
Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis (2007) 1.18
Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology (2006) 1.18
Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol (2009) 1.14
Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol (2005) 1.12
Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol (2003) 1.12
Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells. J Virol (2010) 1.09
The highly conserved orthopoxvirus 68k ankyrin-like protein is part of a cellular SCF ubiquitin ligase complex. Virology (2008) 1.08
Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol (2010) 1.07
Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J Virol (2003) 1.05
IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol (2009) 1.04
RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity. J Infect Dis (2011) 1.03
Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara. J Gen Virol (2006) 1.03
Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res (2003) 1.03
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother (2004) 1.03
Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent. J Immunol (2010) 1.02
Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol Biol (2012) 1.02
Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease. J Immunol (2009) 1.02
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol (2005) 1.01
Virally delivered cytokines alter the immune response to future lung infections. J Virol (2007) 1.01
Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine (2008) 1.00
Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J Gen Virol (2006) 0.99
Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens. J Gen Virol (2004) 0.98
Nosocomial pandemic (H1N1) 2009, United Kingdom, 2009-2010. Emerg Infect Dis (2011) 0.98
Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J Virol (2010) 0.97
Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis (2009) 0.97
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines (2009) 0.96
Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques (2003) 0.96
Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-β-dependent induction of pro-apoptotic Noxa. PLoS Pathog (2011) 0.96
Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus. Clin Diagn Lab Immunol (2004) 0.96
The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung. PLoS One (2010) 0.96
MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One (2009) 0.95
The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respir Res (2005) 0.95
Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine (2002) 0.95
Differences between T cell epitopes recognized after immunization and after infection. J Immunol (2002) 0.95
Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect (2004) 0.94
Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol (2014) 0.94
Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol (2002) 0.93
Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion. Eur J Immunol (2010) 0.92
Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol (2013) 0.92
Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog (2012) 0.91
Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One (2011) 0.91
Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol (2010) 0.91
Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis (2012) 0.91
Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies. Vaccine (2013) 0.90
Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts. J Virol (2009) 0.90
Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res Hum Retroviruses (2007) 0.89
Live viral vectors: vaccinia virus. Methods Mol Med (2003) 0.88
Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine (2013) 0.87
Comparison of CATs, CURB-65 and PMEWS as triage tools in pandemic influenza admissions to UK hospitals: case control analysis using retrospective data. PLoS One (2012) 0.87
The comparative clinical course of pregnant and non-pregnant women hospitalised with influenza A(H1N1)pdm09 infection. PLoS One (2012) 0.87
The poxviral scrapin MV-LAP requires a myxoma viral infection context to efficiently downregulate MHC-I molecules. Virology (2005) 0.87
Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies. J Immunol (2007) 0.86
Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques. J Gen Virol (2002) 0.85
Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man. Int J Cancer (2004) 0.85
Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003. Virus Res (2004) 0.85